Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
Type:
Application
Filed:
March 17, 2022
Publication date:
June 30, 2022
Applicant:
CURASIGHT A/S
Inventors:
Andreas KJAER, Morten PERSSON, Jacob MADSEN
Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
April 26, 2022
Assignee:
Curasight A/S
Inventors:
Andreas Kjaer, Morten Persson, Jacob Madsen
© 2024 Justia
